Do we need all that emicizumab?

Haemophilia. 2022 Mar;28(2):e53-e55. doi: 10.1111/hae.14483. Epub 2021 Dec 30.

Authors

Anna-Elina Lehtinen¹, Riitta Lassila^{1

2}

Affiliations

¹ Helsinki University Hospital, Coagulation Disorders Unit, Department of Haematology, Comprehensive Cancer Centre, Helsinki, Finland.
² Program Unit for Systems Oncology, University of Helsinki, Helsinki, Finland.

PMID: 34970820
DOI: 10.1111/hae.14483

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Bispecific* / pharmacology
Antibodies, Bispecific* / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Factor VIII
Hemophilia A* / drug therapy
Humans

Substances

Antibodies, Bispecific
Antibodies, Monoclonal, Humanized
emicizumab
Factor VIII